Neema Yazdani, a Program in Biomolecular Pharmacology Ph.D. graduate student, has be selected to present a platform presentation at the Tuesday, November 10, 2015 Genome Science Institute’s (GSI) Annual Research Symposium. Neema’s presentation is entitled, ‘HnRNP H1 regulates the stimulant and addictive properties of methamphetamine: Transcriptomic and spliceomic analyses uncover novel neurodevelopmental mechanisms” and is based upon the research he is carrying out in the Laboratory of Addiction Genetics in the Department of Pharmacology & Experimental Therapeutics under the mentorship of Dr. Camron Bryant.
The GSI symposium will be held in Hiebert Lounge, L-14th Floor in the School of Medicine from 12:00 to 5:00 p.m. and will include both poster sessions from 12:30 to 2:30 p.m. and platform presentations from 2:30 to 4:30 p.m. The awards ceremony will immediate follow the platform presentations.
Congratulations to Sanghee Lim on being awarded a 2015 Medical Student Research Grant from the Melanoma Research Foundation for his proposal, “Defining Novel Mechanisms of Genome Instability in Melanoma.” The Medical Student Research Grant is awarded for a one-year period in order “to provide opportunities and funding for medical students to engage in short clinical or laboratory-based research projects focused on better understanding the biology and treatment of melanoma.” Sanghee is one of six medical students who received the nationally competitive award this year.
An MD/PhD student Program in Biomolecular Pharmacology, Sanghee is working under the guidance of Dr. Neil Ganem, Assistant Professor of Pharmacology & Experimental Therapeutics and Medicine, in the Laboratory of Cancer Cell Biology at the Shamim and Ashraf Dahod Breast Cancer Research Laboratories. His work is aimed at defining the mechanisms that give rise to chromosome instability in human melanoma. In particular, Sanghee is testing whether activating mutations in the oncogene BRAF, which occur in ~80% of all melanomas, directly promote mitotic defects.
Great job, Sanghee! Keep up the great work.
Neema Yazdani is one of two graduate students selected for the 2015 “Outstanding Graduate Student Travel Award” for the 17th Annual International Behavioral and Neural Genetics Society (IBANGS) Meeting in Uppsala, Sweden. Neema is a third year PhD candidate and Program in Biomolecular Pharmacology student in the Laboratory of Addiction Genetics under the mentorship of Camron D. Bryant, Ph.D., Assistant Professor of Pharmacology and Psychiatry. As a recipient of this award, Neema is invited to present his research as an oral presentation titled, “Hnrnph1 is a quantitative trait gene for methamphetamine sensitivity”. Neema’s efforts in generating and phenotyping TALENs-targeted Hnrnph1 knockout mice combined with striatal transcriptome analysis via RNA-seq led to the identification of Hnrnph1 as a novel quantitative trait gene involved in the stimulant response to methamphetamine. His transcriptome results suggest that Hnrnph1 could regulate the neural development of the mesocorticolimbic circuitry which would have widespread implications for understanding the etiology of a variety of neurobiological disorders involving a dysregulation of dopamine transmission.
Junior faculty arrive at Boston University full of ambition and with a head full of ideas, but they often have relatively little money for research. So being awarded a Peter Paul Career Development Professorship can feel like winning the lottery; winners receive an annual stipend of $40,000 for three years to pursue their research interests.
For some, it can even seem too good to be true.
“Once I received the email, I asked if they had the right Professor Gonzales,” says Ernest Gonzales, a School of Social Work assistant professor of human behavior. Gonzales, who had no idea that he had been nominated for the award, says the reply from the provost’s office was immediate: “Yes, Ernest, it’s you!”
Peter Paul Professorships were also awarded to Rachel Flynn, a School of Medicine assistant professor of pharmacology and experimental therapeutics, and to Jacob Bor, a School of Public Health assistant professor of global health at the Center for Global Health & Development. University trustee Peter Paul (GSM’71) created the professorships named for him in 2006 with a $1.5 million gift, later increased to $2.5 million. Jean Morrison, BU provost, and President Robert A. Brown select recipients from faculty who are holding their first professorship, have arrived within the last two years, and have been recommended by deans and department chairs.
“It is a privilege to witness the development of talented young scholars into outstanding teachers and researchers,” says Morrison. “From the discovery of novel new cancer treatments and effective approaches to the HIV epidemic to improving conditions for an aging workforce, Professors Bor, Flynn, and Gonzales are fulfilling—and in many ways exceeding—the promise we saw in them when they joined the BU community. We are enormously proud of the important work they’re performing and excited to help advance their research careers.”
Gonzales, who earned a doctorate from Washington University in St. Louis, arrived at the University in July 2013. He is still thinking about how to use the award. He currently juggles several interdisciplinary research projects that focus on productive aging, structural discrimination in and outside of the workforce, and “unretirement”—the practice of retirees returning to work.
His initial findings suggest that the groups most vulnerable to ageism are workers under 30 and those 55 and older. Employees who fall within these ranges face social exclusion and questions about their professionalism or competence. Gonzales is also examining how early life experiences can predict difficult work trajectories later in life. Someone who enters the workforce at 17 with a high school diploma will likely work more physically demanding jobs—such as construction and manufacturing—that wear on their bodies and make it difficult to remain in the workforce long-term.
Gonzales also compares US practices to those in European countries, like Germany, where Chancellor Angela Merkel’s government recently enacted a policy that allows people who have worked 45 years to retire with full benefits. He believes these individuals will relax, recuperate, and eventually return to the workforce—a theory he’s calling “Triple R.”
“I think we have a lot to learn from other nations,” says Gonzales, who would like to conduct cross-national research to see how this and other productive aging policies affect workers’ health and economic standing, with the eventual goal of proposing policy and legislation in the United States.
Flynn, who earned a doctoral degree in cancer biology from the University of Massachusetts Medical School, has been at BU since June 2013. She studies the role telomeres, repetitive DNA sequences that cap the ends of chromosomes, play in cancer development. Each time a cell divides, Flynn says, it loses a chunk of telomere instead of more essential genes further upstream. When telomeres get too short, cells either stop growing or die.
“That is the aging process,” she says. But cancer cells have a way to “highjack this mechanism. When a telomere starts to get shorter, cancer outsmarts it” by reactivating the mechanism that keeps it growing forever.
Telomeres maintain their length using two pathways. Flynn’s lab studies the pathway used by osteosarcoma and glioblastoma—rare and lethal cancers of the bone and brain—and hopes to identify novel treatments that would target this highjacked pathway to better manage the cancers.
So far, Flynn has seen promising results. One compound she’s testing in vitro doesn’t just stop cancer cells from growing, but completely obliterates them—and with minimal effects to surrounding healthy cells. The next step is to test the compound in mouse models.
“If it works as well as it does in a dish, it’ll be amazing,” she says.
Flynn will use the award to hire lab personnel and to buy reagents. “It’s a tremendous opportunity to represent Peter Paul and have money to build my lab,” she says, “but the real goal is to raise the bar, to elevate cancer research at BU.”
Bor, who earned a doctorate at the Harvard University School of Public Health, came to BU in September 2013. He applies the tools of microeconomic models and natural experiments to the field of public health.
“Economics puts an emphasis on the individual; each person is making the best decision for themselves,” Bor says. “At least, that’s the theory.” He looks at decision-making and behavior in a larger economic context to determine what effects they have on health.
Across southern Africa, there’s an elevated HIV infection rate for young women. There are also “high levels of transactional sex,” Bor says. “Maybe if we can expand the choice set of young women so that they can make the best decisions for themselves, we can give them economic opportunities to avoid these relationships.”
In Botswana, he says, the government changed the structure of secondary school so that young women were encouraged to attend. The move resulted in a decrease in HIV infections within that population, he says.
With the award, Bor plans to recruit more doctoral students and research assistants to tackle the papers he’s been dreaming of writing, especially on questions related to South Africa’s HIV treatment program.
“The goal is to rigorously turn these out,” Bor says, “and the faster we do so, the better monies are allocated and the more lives can be saved.”Original article posted on BU Today.
Joon Y. Boon, a graduate student in the Department of Pharmacology & Experimental Therapeutics in the joint Biomolecular Pharmacology and Biomedical Neuroscience Prorgam, has won the Perdana Scholar Award from the Malaysian Department of Education.
This prestigious honor, awarded to Malaysian national students studying in the United States, “aims to identify, document, promote, and award Malaysian students who have excelled in areas such as academic, leadership, sports, entrepreneurship, inventions, and research.” The Perdana Award specifically honors a student who has attained the highest overall level of achievement.
Joon will fly to New York City later this month to receive the award in person from Malaysian Prime Minister Najib. Hat’s off to Joon Y. and her mentor for this amazing achievement! Congratulations!
Dr. Sophie Desbiens, formerly Principal Associate at Decision Resources, has accepted a position as Assistant Director for Adaptive Licensing at MIT’s Center for Biomedical Innovation in the New Drug Development Paradigms (NEWDIGS) program.
According to the NEWDIGS website, the program “is a unique collaborative ‘think and do’ tank focused on enhancing the capacity of the global biomedical innovation system to more reliable and sustainably deliver new, better, affordable therapeutics to the right patients faster.
By bringing together diverse collaborators within a safe haven setting, and leveraging MIT expertise in systems engineering, this group is well positioned to inform and enable meaningful high-impact change involving the coordinated evolution of technologies, processes, policies, and people required to achieve its mission.”
Dr. Sophie Desbiens completed her dissertation work under the mentorship of Dr. David H. Farb, Professor and Chair of Pharmacology, in the Laboratory of Molecular Neurobiology and graduated in 2009. The title of her dissertation was “Therapeutic Agents for Cocaine Addiction: A Systems Pharmacology Approach.”
Congrats on the new position, Sophie!
Iriny Ekladious, a second year PhD student in the joint Biomedical Engineering and Biomolecular Pharmacology Program, was recently awarded the National Science Foundation Graduate Research Fellowship.
The program “recognizes and supports outstanding graduate students” pursuing graduate degrees in various NSF-supported programs across the country and “has a long history of selecting recipients who achieve high levels of success in their future academic and professional careers.”
This year alone, the National Science Foundation received over 14,000 competitive applications and only made 2,000 fellowship award offers. The chosen fellows “are anticipated to become knowledge experts who can contribute significantly to research, teaching, and innovations in science and engineering.”
Iriny was also recently recognized for her service to the Boston University community as a Resident Assistant for Boston University’s Women in Science & Engineering (WISE) specialty housing. In an effort to create more support for women planning to major in STEM programs, BU opened a specialty community residence.
“It’s important to have a community of other women when you’re studying in the STEM fields,” says resident assistant Iriny Ekladious (ENG’17), a second year graduate student. “It can be intimidating, and women often feel outnumbered. Having a community like this gives students confidence and empowers them to say, ‘I’m good at this and I can do this,’ despite all the hurdles.”
Iriny’s dissertation work involves synthesizing, characterizing, and assessing the efficacy of pH-sensitive expansile nanoparticles for the local delivery of chemotherapeutic agents under the mentorship of Dr. Mark Grinstaff in the Center for Nanoscience and Nanobiotechnology.
We are thrilled that Iriny has been recognized for extraordinary contributions in the engineering and field and for her exemplary leadership serving undergraduates in the WISE house!
Selected excerpts taken from an article originally published by BU Today on April 16, 2014.
Hui Feng spends a lot of time staring through zebra fish. Through because these vertebrates, which have a great deal of genetics in common with humans, are transparent. In fact, one particular breed, called Casper—after the Friendly Ghost—is so phantasmal that Feng says that “you can read newspapers through this fish.”
Feng doesn’t read the news through them, though. The School of Medicine assistant professor of pharmacology and medicine is more interested in tracking the pathways of dyed tumor cells as they metastasize through the zebra fish’s vasculature, which is tinted a contrasting color. In the less than two years since her tank-filled lab opened, she has identified genes that, when blocked with targeted treatments, could prevent the metastasis of certain types of cancer, like the most stubborn forms of leukemia.
In recognition of her groundbreaking work, Feng was awarded the Ralph Edwards Career Development Professorship, which recognizes MED researchers. The award was made possible this year by the estate of obstetrician and gynecologist Ralph Edwards (MED’52).
Feng, director of the Laboratory of Zebrafish Genetics & Cancer Therapeutics, says the honor reminds her that University officials appreciate faculty research and they want to support it. “It’s not just about the money,” she says. “The spiritual or mental support really means so much to us.”
Karen Antman, MED dean and Medical Campus provost, recalls the researcher’s discoveries early in her career, which found their way to top-tier research journals, including Nature, Cell Biology, Cancer Cell, the Journal of Experimental Medicine, and PNAS. A graduate of Beijing Medical University, Feng completed a master’s in cardiovascular pharmacology at Peking Union Medical College and a doctorate in cellular biology at the University of Georgia.
“Since joining the School of Medicine faculty,” Antman says, “Dr. Feng has demonstrated an exceptional level of scholarship, mentorship, teaching, and collegiality and quickly established herself as an independent research scientist, effectively and efficiently setting up a robust research program.”
Feng is one of three assistant professors who were given career development awards, which recognize junior faculty who have been at the University for less than two years and have held no prior professorships. Cornel Ban, a College of Arts & Sciences assistant professor of international relations, received the inaugural Stuart and Elizabeth Pratt Career Development Professorship, dedicated to CAS scholars. And Nachiketa Sahoo, a School of Management assistant professor of information systems, was awarded the Reidy Family Career Development Professorship, which has recognized faculty members in SMG and the College of Engineering in alternating years since 2010.
Contributions from BU trustee Stuart W. Pratt (CAS’69) and his wife, Elizabeth, and trustee Richard D. Reidy (SMG’82) and his wife, Minda G. Reidy (SMG’82, GSM’84) made the professorships possible.
Each award comes with a three-year nonrenewable stipend used to support scholarly or creative work and to cover a portion of the faculty member’s salary. Deans of the respective schools or colleges nominate faculty for these honors, and the Office of the Provost makes the final selections.
“We are extremely grateful to Stuart and Elizabeth Pratt, Richard and Minda Reidy, and posthumously, Ralph Edwards for their generosity and for the vision they’ve shown in supporting the future of these very important fields,” says Jean Morrison, University provost and chief academic officer. These three professors were recognized for “their extraordinary accomplishments in areas of study, passion for the creation and transmission of knowledge, and their efforts to enhance the student experience.”
Ban’s research has focused on economic issues in Brazil, Spain, and Romania, and spans three principal topics: international finance, international economic organizations, and the diffusion of international economic ideas. He describes his first book, Governing Crises: The International Politics of Crisis Economics from Bretton Woods to the Great Recession, not yet published, as “a cautionary tale about how much we don’t know about how the financial markets work.” He is an expert on the failure of economic models used by governments or international banks to predict the financial crisis that swept the world within the past decade.
Ban earned a bachelor’s from Babes-Bolyai University, in Romania, a master’s degree from the University of Delaware, and a doctorate in political science from the University of Maryland. He says the award will give him the time and funding to launch his next book project, which will focus on the dynamics of international finance over the past couple of decades. “Without this kind of support,” he says, “I could not get it done.”
Andrew Bacevich, a CAS professor of history and international relations and acting chair of international relations, calls Ban an “emerging superstar” in the department. “Since his arrival a year ago, he has become a valued asset,” he says. “His performance as a teacher and scholar has demonstrated that he is precisely the sort of young faculty member for whom the Stuart and Elizabeth Pratt Career Development Professorship is designed.”
Sahoo holds a master’s degree in knowledge discovery and data mining and a doctorate in information systems and management, both from Carnegie Mellon University. His current research focus is on improving personalized information filtering techniques, such as that used by Netflix and Amazon, to help customers find products that best match their past interests. Recognizing that people are dynamic and that their preferences change over time, he has adjusted these filtering techniques so that they show more accurate recommendations across a variety of platforms.
In a separate branch of research, Sahoo is analyzing the messages exchanged between individuals on corporate social media, such as blogs, to identify expertise that exists inside a company.
“New technologies to help people connect to each other are exacerbating the problem of information overload at a personal level,” says Sahoo. “There is too much information to sift through and there is limited time. It’s important to develop tools and techniques that help us find the bits of relevant information faster.”
Sahoo says he will use the award to hire a research assistant to help with data collection and analysis.
“Dr. Sahoo is a wonderful addition to our faculty: a productive researcher, a great colleague, and a committed teacher,” says Kenneth Freeman, SMG’s Allen Questrom Professor and Dean.
Maya Woodbury was recently awarded the Predoctoral Fellowship in Pharmacology/Toxicology through the PhRMA Foundation. The title of her approved proposal is “miR-155/STAT3 signaling: a novel pharmacological target for Down syndrome.” For this project, she will receive financial support for her research in the amount of $20,000 per year for two years. The Foundation only awards about 10 such grants nationally each year.
According to the PhRMA Foundation’s 2012 Annual Report, “the mission of the PhRMA Foundation is to support young scientists in disciplines important to the pharmaceutical industry by awarding them competitive research fellowships and grants at a critical point at the outset of their careers. The aim is to encourage young scientists who will be the leaders of tomorrow to pursue careers in research and education related to drug discovery.”
Maya is currently a student in the Graduate Program for Neuroscience and the Biomolecular Pharmacology Program through the Department of Pharmacology & Experimental Therapeutics at Boston University School of Medicine. She works in the Laboratory of Molecular NeuroTherapeutics under the mentorship of Dr. Tsuneya Ikezu.
Kenneth J. Rhodes, Ph.D., Vice President of Neurology Discovery at Biogen Idec and an alumni of the Boston University Pharmacology Training Program, led the team of researchers that developed Tecfidera, an oral medication that defends against relapsing Multiple Sclerosis (MS).
The Food and Drug Administration recently approved Tecfidera, also known as dimethyl fumarate, for treating relapsing multiple sclerosis. This new drug delays progression of physical disability and slows the development of brain lesions associated with MS. It also reduces the inflammation caused when the immune system attacks myelin, which ultimately results in less damage to myelin in the body. In a Biogen Idec press release, Dr. Kenneth Rhodes stated that, “these exciting results support further research, as the data suggest that neublastin may have the potential to promote sensory neuronal regeneration and functional recovery following injury. The neublastin program is part of Biogen Idec’s commitment to innovative neurological science and discovery.”
According to the Boston Business Journal, Tecfidera “tops the list of the biggest potential revenue-generating drugs launched so far this year in the U.S., with expected sales of $2.9 billion by 2018.”
Dr. Kenneth Rhodes joined Biogen Idec in May 2007 after spending ten years in the Neuroscience Department at Wyeth, where he also led neurodegeneration drug discovery teams researching MS among epilepsy, stroke, Parkinson’s and Alzheimer’s disease. He served as a postdoctoral trainee under the mentorship of Dr. David H. Farb, Professor and Chair of Pharmacology at Boston University School of Medicine, from 1992-1993. Dr. Rhodes has published over 50 research papers in peer-reviewed journals such as Nature, Neuron, and the Journal of Neuroscience and most recently was the Keynote Speaker for the 2013 BU-Pfizer Symposium on “Therapeutic Innovation: Oxidative Stress and the Next Generation of Discovery” held November 5, 2013.